{"id":1732,"date":"2019-09-17T20:05:57","date_gmt":"2019-09-17T18:05:57","guid":{"rendered":"https:\/\/idibell.cat\/?page_id=1732"},"modified":"2024-12-17T15:30:48","modified_gmt":"2024-12-17T14:30:48","slug":"prett","status":"publish","type":"page","link":"https:\/\/idibell.cat\/recerca\/area-de-cancer\/programa-de-mecanismes-moleculars-i-terapia-experimental-en-oncologia-oncobell\/prett\/","title":{"rendered":"Recerca precl\u00ednica i experimental dels tumors tor\u00e0cics (PReTT)"},"content":{"rendered":"\n<h1>\n\t\tRecerca precl\u00ednica i experimental dels tumors tor\u00e0cics (PReTT)\n\t<\/h1>\n<h3>\n\t\tResum\n\t<\/h3>\n\t<p>El grup PReTT es centra en l&#8217;estudi de noves estrat\u00e8gies terap\u00e8utiques en tumors tor\u00e0cics combinant investigaci\u00f3 molecular b\u00e0sica, translacional amb un enfoc orientat al pacient, i bioinform\u00e0tica, aix\u00ed com en el disseny i desenvolupament d&#8217;assajos cl\u00ednics. Pel que fa a la investigaci\u00f3 b\u00e0sica, estudiem els mecanismes pels quals les c\u00e8l\u00b7lules tumorals moren en resposta a diferents tractaments i est\u00edmuls. Analitzem les respostes tant a nivell cel\u00b7lular com del microambient tumoral, incl\u00f2s el sistema immunol\u00f2gic i l&#8217;estat metab\u00f2lic. En l&#8217;aspecte translacional, el nostre enfocament \u00e9s la validaci\u00f3 de biomarcadors de resposta al tractament i de diagn\u00f2stic per tal de millorar la gesti\u00f3 cl\u00ednica dels pacients amb tumors tor\u00e0cics. A nivell bioinform\u00e0tic, l&#8217;objectiu \u00e9s millorar l&#8217;estratificaci\u00f3 dels tumors tor\u00e0cics i la identificaci\u00f3 de tractaments potencialment innovadors adaptats a les caracter\u00edstiques moleculars de cada pacient.<\/p>\n<h2>77<\/h2>\n<h2>Publicacions<\/h2>\n\t\t\t\t<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/idibell.cat\/wp-content\/uploads\/2020\/04\/108-mortcelular-cmunozpinedo-def.jpg\" alt=\"108-mortcelular-cmunozpinedo-def\" itemprop=\"image\" height=\"300\" width=\"600\" title=\"108-mortcelular-cmunozpinedo-def\" onerror=\"this.style.display='none'\"  \/>\n\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--label-0\" tabindex=\"0\" aria-controls=\"fl-accordion--panel-0\">L\u00ednies estrat\u00e8giques<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--icon-0\" tabindex=\"-1\"><i title=\"Expand\">Expand<\/i><\/a>\n\t\t\t\t\t<ul>\n<li>Caracteritzaci\u00f3 de les connexions entre el sistema immune-tumor-estroma en tumors tor\u00e0cics per millorar les aproximacions terap\u00e8utiques (Ernest Nadal, Cristina Mu\u00f1oz-Pinedo i Xavier Sol\u00e9)<\/li>\n<li>Estudi de vulnerabilitats metab\u00f2liques en c\u00e0ncer de pulm\u00f3 i mesotelioma pleural maligne (Cristina Mu\u00f1oz-Pinedo i Ernest Nadal)<\/li>\n<li>Mecanismes moleculars d&#8217;apoptosi i altres formes de mort cel\u00b7lular indu\u00efdes per desafiaments metab\u00f2lics i isqu\u00e8mia (Cristina Mu\u00f1oz-Pinedo)<\/li>\n<li>Estudi d&#8217;alteracions gen\u00f2miques som\u00e0tiques i de l\u00ednia germinal en tumors tor\u00e0cics en teixit tumoral i bi\u00f2psia l\u00edquida (Ernest Nadal i Xavier Sol\u00e9)<\/li>\n<li>Disseny i desenvolupament d&#8217;assaigs cl\u00ednics amb un fonament cient\u00edfic s\u00f2lid (Ernesto Nadal)<\/li>\n<li>Estratificaci\u00f3 de tumors tor\u00e0cics basada en la integraci\u00f3 computacional de dades \u00f2miques (Xavier Sol\u00e9 i Ernest Nadal)<\/li>\n<li>Identificaci\u00f3 de tractaments personalitzats mitjan\u00e7ant la integraci\u00f3 de dades farmacogen\u00f2miques a gran escala i perfils validats de resposta a f\u00e0rmacs (Xavier Sol\u00e9)<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--label-1\" tabindex=\"0\" aria-controls=\"fl-accordion--panel-1\">Publicacions seleccionades<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--icon-1\" tabindex=\"-1\"><i title=\"Expand\">Expand<\/i><\/a>\n\t\t\t\t\t<ul>\n<li>Nadal,E;Rodr\u00edguez Abreu,D;Sim\u00f3,M;Massut\u00ed,B;Juan,O;Huidobro,G;L\u00f3pez,R et al, <strong>Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases<\/strong> (Atezo-Brain, GECP17\/05), J. Clin. Oncol., 2023;41(28):4478-4485, doi:10.1200\/JCO.22.02561<\/li>\n<li>Hijazo Pechero,S;Alay,A;Cordero,D;Marin,R;Vilari\u00f1o,N;Palmero,R;Brenes,J et al, <strong>Transcriptional analysis of landmark molecular pathways in lung adenocarcinoma results in a clinically relevant classification with potential therapeutic implications<\/strong>, Mol. Oncol., 2023;18(2):453-470, doi:10.1002\/1878-0261.13550<\/li>\n<li>Favaro,F;Both,D;Derks,I;Spaargaren,M;Munoz Pinedo,C;Eldering,E, <strong>Negligible role of TRAIL death receptors in cell death upon endoplasmic reticulum stress in B-cell malignancies<\/strong>, Oncogenesis, 2023;12(1):6-6, doi:10.1038\/s41389-023-00450-w<\/li>\n<li>Provencio,M;Nadal,E;Gonz\u00e1lez Larriba,JL;Mart\u00ednez Mart\u00ed,A;Bernab\u00e9,R;Bosch Barrera,J;Casal Rubio,J et al, <strong>Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer<\/strong>, N. Engl. J. Med., 2023;389(6):doi:10.1056\/NEJMoa2215530<\/li>\n<li>Cho,BC;Lee,JS;Wu,YL;Cicin,I;Dols,MC;Ahn,MJ;Cuppens,K et al, <strong>Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial<\/strong>, J. Thorac. Oncol., 2023;18(12):1731-1742, doi:10.1016\/j.jtho.2023.08.018<\/li>\n<\/ul>\n\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--label-2\" tabindex=\"0\" aria-controls=\"fl-accordion--panel-2\">Projectes seleccionats<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--icon-2\" tabindex=\"-1\"><i title=\"Expand\">Expand<\/i><\/a>\n\t\t\t\t\t<ul>\n<li>MCI22017. <strong>Estr\u00e9s metab\u00f3lico en c\u00e1ncer: la respuesta integrada al estr\u00e9s como diana terap\u00e9utica en c\u00e1ncer de pulm\u00f3n de c\u00e9lula no peque\u00f1a (APOMETALUNG2)<\/strong>. Ministerio de Ciencia e Innovaci\u00f3n. Budget: 312.500\u20ac. 2023-2026. PI: MU\u00d1OZ PINEDO, CRISTINA.<\/li>\n<li>FIS21087. <strong>Nuevas estrategias terap\u00e9uticas en mesotelioma pleural maligno basadas en inmunoterapia y terapias dirigidas a ciclo celular y senescencia celular<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 195.415\u20ac. 2022-2024. PI: Nadal Alforja, Ernesto Samuel.<\/li>\n<li>20MAR002. <strong>Modulating glycemia to improve benefit of chemoradiotherapy and immunotherapy in Non-Small Cell Lung Carcinoma<\/strong>. Fundaci\u00f3 La Marat\u00f3 de TV3. Budget: 200.000\u20ac. 2020-2024. PI: MU\u00d1OZ PINEDO, CRISTINA.<\/li>\n<li>2022-158-1. <strong>A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Bemarituzumab Monotherapy and Combination with Docetaxel in Subjects with Squamous-Cell Non-Small-Cell Lung Cancer (FORTITUDE-201)<\/strong>. Amgen, S.A. Budget: 463.068\u20ac. 2022- . PI: Nadal Alforja, Ernesto Samuel.<\/li>\n<li>20ACL245. <strong>ESTUDIO DE FASE III, MULTIC\u00c9NTRICO, ALEATORIZADO, ABIERTO Y CONTROLADO PARA EVALUAR LA EFICACIA, LA SEGURIDAD Y LA FARMACOCIN\u00c9TICA DE ATEZOLIZUMAB EN COMBINACI\u00d3N CON CABOZANTINIB EN COMPARACI\u00d3N CON DOCETAXEL EN MONOTERAPIA EN PACIENTES CON C\u00c1NCER DE PULM\u00d3N NO MICROC\u00cdTICO TRATADO PREVIAMENTE CON UN ANTICUERPO ANTI-PD-L1\/PD-1 Y QUIMIOTERAPIA CON PLATINO<\/strong>. Roche Farma, S.A.. Budget: 59.904\u20ac. 2020- . PI: Nadal Alforja, Ernesto Samuel.<\/li>\n<\/ul>\n\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--label-3\" tabindex=\"0\" aria-controls=\"fl-accordion--panel-3\">M\u00e9s informaci\u00f3<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--icon-3\" tabindex=\"-1\"><i title=\"Expand\">Expand<\/i><\/a>\n\t\t\t\t\t<p>El grup ha desxifrat com i per qu\u00e8 moren les c\u00e8l\u00b7lules en condicions de falta de nutrients.<\/p>\n<em>Proyectos financiados por el Instituto de Salud Carlos III (ISCIII) y cofinanciados por el Fondo Europeo de Desarrollo Regional (FEDER):<br \/>\n<\/em><strong>Se\u00f1alizaci\u00f3n c\u00e9lula-c\u00e9lula y muerte celular en respuesta a la falta de nutrientes y a la inhibici\u00f3n del metabolismo tumoral<br \/>\n<\/strong>PI13\/00139. 01\/2014-09\/2017. 127.500 \u20ac. IP: Cristina Mu\u00f1oz Pinedo.<br \/>\nLas c\u00e9lulas tumorales son dependientes de la glucosa como fuente de energ\u00eda y tambi\u00e9n como fuente del carbono necesario para la producci\u00f3n de macromol\u00e9culas. Por este motivo, y tambi\u00e9n debido a varias mutaciones oncog\u00e9nicas, son m\u00e1s sensibles a la falta de glucosa que las c\u00e9lulas no transformadas. En este proyecto buscamos caracterizar respuestas intr\u00ednsecas a la falta de glucosa y al tratamiento con 2-deoxiglucosa; y mol\u00e9culas secretadas que medien la comunicaci\u00f3n c\u00e9lula-c\u00e9lula en respuesta a estos est\u00edmulos.\n<p><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/idibell.cat\/wp-content\/uploads\/2019\/12\/7mUdUAq.png\" alt=\"\" width=\"249\" height=\"150\" \/><\/p>\n\t\t\t\t<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/idibell.cat\/wp-content\/uploads\/2022\/11\/Cristina-Munoz-Pinedo22-150x150.jpg\" alt=\"Cristina-Mu\u00f1oz-Pinedo22\" itemprop=\"image\" height=\"150\" width=\"150\" title=\"Cristina-Mu\u00f1oz-Pinedo22\" onerror=\"this.style.display='none'\"  \/>\n<h4>\n\t\tMu\u00f1oz Pinedo, Cristina\n\t<\/h4>\n<h4>\n\t\t<a href=\"mailto:cmunoz@idibell.cat\" title=\"cmunoz@idibell.cat\" target=\"_blank\" rel=\"noopener\">\n\t\tcmunoz@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/idibell.cat\/wp-content\/uploads\/2019\/09\/nadal-alforja-ernesto-samuel-150x150.jpg\" alt=\"Nadal Alforja, Ernesto Samuel\" itemprop=\"image\" height=\"150\" width=\"150\" title=\"nadal-alforja-ernesto-samuel\" onerror=\"this.style.display='none'\"  \/>\n<h4>\n\t\tNadal Alforja, Ernest\n\t<\/h4>\n<h4>\n\t\t<a href=\"mailto:enadal@idibell.cat\" title=\"enadal@idibell.cat\" target=\"_blank\" rel=\"noopener\">\n\t\tenadal@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n<h2>\n\t\tInvestigadors principals\n\t<\/h2>\n\t\t\t\t<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/idibell.cat\/wp-content\/uploads\/2022\/11\/Cristina-Munoz-Pinedo22-150x150.jpg\" alt=\"Cristina-Mu\u00f1oz-Pinedo22\" itemprop=\"image\" height=\"150\" width=\"150\" title=\"Cristina-Mu\u00f1oz-Pinedo22\" onerror=\"this.style.display='none'\"  \/>\n<h4>\n\t\tMu\u00f1oz Pinedo, Cristina\n\t<\/h4>\n<h4>\n\t\t<a href=\"mailto:cmunoz@idibell.cat\" title=\"cmunoz@idibell.cat\" target=\"_blank\" rel=\"noopener\">\n\t\tcmunoz@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/idibell.cat\/wp-content\/uploads\/2019\/09\/nadal-alforja-ernesto-samuel-150x150.jpg\" alt=\"Nadal Alforja, Ernesto Samuel\" itemprop=\"image\" height=\"150\" width=\"150\" title=\"nadal-alforja-ernesto-samuel\" onerror=\"this.style.display='none'\"  \/>\n<h4>\n\t\tNadal Alforja, Ernest\n\t<\/h4>\n<h4>\n\t\t<a href=\"mailto:enadal@idibell.cat\" title=\"enadal@idibell.cat\" target=\"_blank\" rel=\"noopener\">\n\t\tenadal@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/idibell.cat\/wp-content\/uploads\/2023\/02\/Ivan-Macia-Vidueira-150x150.jpg\" alt=\"Ivan-Mac\u00eda-Vidueira\" itemprop=\"image\" height=\"150\" width=\"150\" title=\"Ivan-Mac\u00eda-Vidueira\" onerror=\"this.style.display='none'\"  \/>\n<h4>\n\t\tIvan Mac\u00eda Vidueira\n\t<\/h4>\n<h4>\n\t\t<a href=\"mailto:imacia@idibell.cat\" title=\"imacia@idibell.cat\" target=\"_blank\" rel=\"noopener\">\n\t\timacia@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n<h4>\n\t\tENLLA\u00c7OS RELACIONATS\n\t<\/h4>\n<h4>\n\t\t<a href=\"https:\/\/www.facebook.com\/apoptosislab\/\" title=\"Facebook: \"Cell Death\"\" target=\"_blank\" rel=\"noopener\">\n\t\tFacebook: &#8220;Cell Death&#8221;\n\t\t<\/a>\n\t<\/h4>\n<h4>\n\t\t<a href=\"http:\/\/www.apoptosis.es\/\" title=\"ApoList archive\" target=\"_blank\" rel=\"noopener\">\n\t\tApoList archive\n\t\t<\/a>\n\t<\/h4>\n<h4>\n\t\t<a href=\"http:\/\/www.cancer-metabolism.org\/\" title=\"Lab MetaboList archive: Recopilaci\u00f3n\" target=\"_blank\" rel=\"noopener\">\n\t\tLab MetaboList archive: Recopilaci\u00f3n\n\t\t<\/a>\n\t<\/h4>\n<h4>\n\t\t<a href=\"http:\/\/www.metacan.eu\/\" title=\"Marie Curie network META-CAN\" target=\"_blank\" rel=\"noopener\">\n\t\tMarie Curie network META-CAN\n\t\t<\/a>\n\t<\/h4>\n<h4>\n\t\t<a href=\"https:\/\/twitter.com\/meta_canproject\" title=\"@meta_canproject\" target=\"_blank\" rel=\"noopener\">\n\t\t@meta_canproject\n\t\t<\/a>\n\t<\/h4>\n<h4>\n\t\t<a href=\"http:\/\/www.deathbase.org\/\" title=\"DeathBase\" target=\"_blank\" rel=\"noopener\">\n\t\tDeathBase\n\t\t<\/a>\n\t<\/h4>\n<h4>\n\t\t<a href=\"http:\/\/www.apored.es\/\" title=\"Apored\" target=\"_blank\" rel=\"noopener\">\n\t\tApored\n\t\t<\/a>\n\t<\/h4>\n<h4>\n\t\t<a href=\"https:\/\/twitter.com\/apoptosislab\" title=\"@apoptosislab\" target=\"_blank\" rel=\"noopener\">\n\t\t@apoptosislab\n\t\t<\/a>\n\t<\/h4>\n<h4>\n\t\t<a href=\"https:\/\/twitter.com\/NadalErnest\" title=\"@NadalErnest\" target=\"_blank\" rel=\"noopener\">\n\t\t@NadalErnest\n\t\t<\/a>\n\t<\/h4>\n<h2>\n\t\tEquip\n\t<\/h2>\n\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-tabs--label-0\" data-index=\"0\" aria-selected=\"true\" aria-controls=\"fl-tabs--panel-0\" aria-expanded=\"true\" role=\"tab\" tabindex=\"0\">\t\t\t\tCaps de grup\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-tabs--label-1\" data-index=\"1\" aria-selected=\"false\" aria-controls=\"fl-tabs--panel-1\" aria-expanded=\"false\" role=\"tab\" tabindex=\"0\">\t\t\t\tInvestigadors\/es principals\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-tabs--label-2\" data-index=\"2\" aria-selected=\"false\" aria-controls=\"fl-tabs--panel-2\" aria-expanded=\"false\" role=\"tab\" tabindex=\"0\">\t\t\t\tInvestigadors\/es cl\u00ednics\/ques\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-tabs--label-3\" data-index=\"3\" aria-selected=\"false\" aria-controls=\"fl-tabs--panel-3\" aria-expanded=\"false\" role=\"tab\" tabindex=\"0\">\t\t\t\tInvestigadors\/es postdoctorals\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-tabs--label-4\" data-index=\"4\" aria-selected=\"false\" aria-controls=\"fl-tabs--panel-4\" aria-expanded=\"false\" role=\"tab\" tabindex=\"0\">\t\t\t\tInvestigadors\/es predoctorals\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-tabs--label-5\" data-index=\"5\" aria-selected=\"false\" aria-controls=\"fl-tabs--panel-5\" aria-expanded=\"false\" role=\"tab\" tabindex=\"0\">\t\t\t\tSuport cient\u00edfic\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-tabs--label-6\" data-index=\"6\" aria-selected=\"false\" aria-controls=\"fl-tabs--panel-6\" aria-expanded=\"false\" role=\"tab\" tabindex=\"0\">\t\t\t\tSuport administratiu\t\t\t\t<\/a>\n\t\t\t\t\t\tCaps de grup\n\t\t\t\t\t\t\t\t\t\t\t<ul>\n<li>Mu\u00f1oz Pinedo, Cristina<\/li>\n<li>Nadal Alforja, Ernest<\/li>\n<\/ul>\n\t\t\t\t\t\tInvestigadors\/es principals\n\t\t\t\t\t\t\t\t\t\t\t<ul>\n<li>Ivan Mac\u00eda Vidueira<\/li>\n<\/ul>\n\t\t\t\t\t\tInvestigadors\/es cl\u00ednics\/ques\n\t\t\t\t\t\t\t\t\t\t\t<ul>\n<li>Palmero Sanchez, Ramon<\/li>\n<li>Jov\u00e9 Casulleras, Maria<\/li>\n<li>Vilari\u00f1o Quintela, Noelia<\/li>\n<\/ul>\n\t\t\t\t\t\tInvestigadors\/es postdoctorals\n\t\t\t\t\t\t\t\t\t\t\t<ul>\n<li>Gausachs Romero, Mireia<\/li>\n<li>Cordero Romera, David<\/li>\n<li>Hijazo Pechero, Sara<\/li>\n<\/ul>\n\t\t\t\t\t\tInvestigadors\/es predoctorals\n\t\t\t\t\t\t\t\t\t\t\t<ul>\n<li>Alay Badosa, Ania<\/li>\n<li>Collado Rodr\u00edguez, Lidia<\/li>\n<li>Cruz Rodr\u00edguez, Mabel<\/li>\n<li>Jimenez Hernandez Felipe<\/li>\n<li>Mar\u00edn Montes, Ra\u00fal<\/li>\n<li>Sreeram, Iswarya<\/li>\n<li>Plans i Marin, S\u00edlvia<\/li>\n<\/ul>\n\t\t\t\t\t\tSuport cient\u00edfic\n\t\t\t\t\t\t\t\t\t\t\t<ul>\n<li>Barroso Barquilla, David<\/li>\n<li>Ajenjo Bauza, Maria<\/li>\n<li>Delgado De La Iglesia, Eduardo<\/li>\n<li>Palau Gallinat, Didac Nestor<\/li>\n<\/ul>\n\t\t\t\t\t\tSuport administratiu\n\t\t\t\t\t\t\t\t\t\t\t<ul>\n<li>Moreno Caceres, Joaquim<\/li>\n<li>Ruiz Mitjana, Anna<\/li>\n<\/ul>\n<h2>\n\t\tNot\u00edcies relacionades\n\t<\/h2>\n\t<meta itemscope itemprop=\"mainEntityOfPage\" itemtype=\"https:\/\/schema.org\/WebPage\" itemid=\"http:\/\/26392\" content=\"Resultats precl\u00ednics prometedors contra el c\u00e0ncer de pulm\u00f3 amb estrat\u00e8gies innovadores per combatre les resist\u00e8ncies\" \/><meta itemprop=\"datePublished\" content=\"2024-10-22\" \/><meta itemprop=\"dateModified\" content=\"2024-10-22\" \/><meta itemprop=\"name\" content=\"IDIBELL\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2023\/03\/cropped-Marca-B.png\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/author\/comunicacio\/\" \/><meta itemprop=\"name\" content=\"comunicacio\" \/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2024\/10\/NO094-Villanueva-web.jpg\" \/><meta itemprop=\"width\" content=\"1366\" \/><meta itemprop=\"height\" content=\"768\" \/><meta itemprop=\"interactionType\" content=\"https:\/\/schema.org\/CommentAction\" \/><meta itemprop=\"userInteractionCount\" content=\"0\" \/>\t\n\t\t\t\t<a href=\"https:\/\/idibell.cat\/2024\/10\/resultats-preclinics-prometedors-contra-el-cancer-de-pulmo-amb-estrategies-innovadores-per-combatre-les-resistencies\/\" title=\"Resultats precl\u00ednics prometedors contra el c\u00e0ncer de pulm\u00f3 amb estrat\u00e8gies innovadores per combatre les resist\u00e8ncies\"><\/a>\n\t\t\t<a href=\"https:\/\/idibell.cat\/2024\/10\/resultats-preclinics-prometedors-contra-el-cancer-de-pulmo-amb-estrategies-innovadores-per-combatre-les-resistencies\/\" title=\"Resultats precl\u00ednics prometedors contra el c\u00e0ncer de pulm\u00f3 amb estrat\u00e8gies innovadores per combatre les resist\u00e8ncies\">Resultats precl\u00ednics prometedors contra el c\u00e0ncer de pulm\u00f3 amb estrat\u00e8gies innovadores per combatre les resist\u00e8ncies<\/a>\n\t\t\tBy <a href=\"https:\/\/idibell.cat\/author\/comunicacio\/\">comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t  |  \n\t\t\t\t\t\t\t\t\t22\/10\/2024\t\t\t\t\t\t\t\n\t<meta itemscope itemprop=\"mainEntityOfPage\" itemtype=\"https:\/\/schema.org\/WebPage\" itemid=\"http:\/\/25065\" content=\"Se celebra la primera Jornada d'Innovaci\u00f3 sobre el Diagn\u00f2stic i Tractament dels Pacients amb C\u00e0ncer de Pulm\u00f3 al Campus de Bellvitge\" \/><meta itemprop=\"datePublished\" content=\"2024-02-16\" \/><meta itemprop=\"dateModified\" content=\"2024-02-16\" \/><meta itemprop=\"name\" content=\"IDIBELL\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2023\/03\/cropped-Marca-B.png\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/author\/comunicacio\/\" \/><meta itemprop=\"name\" content=\"comunicacio\" \/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2024\/02\/WhatsApp-Image-2024-02-16-at-12.24.33_v1.jpeg\" \/><meta itemprop=\"width\" content=\"1600\" \/><meta itemprop=\"height\" content=\"800\" \/><meta itemprop=\"interactionType\" content=\"https:\/\/schema.org\/CommentAction\" \/><meta itemprop=\"userInteractionCount\" content=\"0\" \/>\t\n\t\t\t\t<a href=\"https:\/\/idibell.cat\/2024\/02\/se-celebra-la-primera-jornada-dinnovacio-sobre-el-diagnostic-i-tractament-dels-pacients-amb-cancer-de-pulmo-al-campus-de-bellvitge\/\" title=\"Se celebra la primera Jornada d'Innovaci\u00f3 sobre el Diagn\u00f2stic i Tractament dels Pacients amb C\u00e0ncer de Pulm\u00f3 al Campus de Bellvitge\"><\/a>\n\t\t\t<a href=\"https:\/\/idibell.cat\/2024\/02\/se-celebra-la-primera-jornada-dinnovacio-sobre-el-diagnostic-i-tractament-dels-pacients-amb-cancer-de-pulmo-al-campus-de-bellvitge\/\" title=\"Se celebra la primera Jornada d'Innovaci\u00f3 sobre el Diagn\u00f2stic i Tractament dels Pacients amb C\u00e0ncer de Pulm\u00f3 al Campus de Bellvitge\">Se celebra la primera Jornada d&#8217;Innovaci\u00f3 sobre el Diagn\u00f2stic i Tractament dels Pacients amb C\u00e0ncer de Pulm\u00f3 al Campus de Bellvitge<\/a>\n\t\t\tBy <a href=\"https:\/\/idibell.cat\/author\/comunicacio\/\">comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t  |  \n\t\t\t\t\t\t\t\t\t16\/02\/2024\t\t\t\t\t\t\t\n\t<meta itemscope itemprop=\"mainEntityOfPage\" itemtype=\"https:\/\/schema.org\/WebPage\" itemid=\"http:\/\/24810\" content=\"Troben com definir ter\u00e0pies dirigides en c\u00e0ncer de pulm\u00f3 gr\u00e0cies a una plataforma de seq\u00fcenciaci\u00f3 gen\u00e8tica\" \/><meta itemprop=\"datePublished\" content=\"2024-01-04\" \/><meta itemprop=\"dateModified\" content=\"2024-01-04\" \/><meta itemprop=\"name\" content=\"IDIBELL\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2023\/03\/cropped-Marca-B.png\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/author\/comunicacio\/\" \/><meta itemprop=\"name\" content=\"comunicacio\" \/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2024\/01\/231219-Conxi-Ernest-002.jpg\" \/><meta itemprop=\"width\" content=\"1366\" \/><meta itemprop=\"height\" content=\"768\" \/><meta itemprop=\"interactionType\" content=\"https:\/\/schema.org\/CommentAction\" \/><meta itemprop=\"userInteractionCount\" content=\"0\" \/>\t\n\t\t\t\t<a href=\"https:\/\/idibell.cat\/2024\/01\/troben-com-definir-terapies-dirigides-en-cancer-de-pulmo-gracies-a-una-plataforma-de-sequenciacio-genetica\/\" title=\"Troben com definir ter\u00e0pies dirigides en c\u00e0ncer de pulm\u00f3 gr\u00e0cies a una plataforma de seq\u00fcenciaci\u00f3 gen\u00e8tica\"><\/a>\n\t\t\t<a href=\"https:\/\/idibell.cat\/2024\/01\/troben-com-definir-terapies-dirigides-en-cancer-de-pulmo-gracies-a-una-plataforma-de-sequenciacio-genetica\/\" title=\"Troben com definir ter\u00e0pies dirigides en c\u00e0ncer de pulm\u00f3 gr\u00e0cies a una plataforma de seq\u00fcenciaci\u00f3 gen\u00e8tica\">Troben com definir ter\u00e0pies dirigides en c\u00e0ncer de pulm\u00f3 gr\u00e0cies a una plataforma de seq\u00fcenciaci\u00f3 gen\u00e8tica<\/a>\n\t\t\tBy <a href=\"https:\/\/idibell.cat\/author\/comunicacio\/\">comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t  |  \n\t\t\t\t\t\t\t\t\t04\/01\/2024\t\t\t\t\t\t\t\n\t<meta itemscope itemprop=\"mainEntityOfPage\" itemtype=\"https:\/\/schema.org\/WebPage\" itemid=\"http:\/\/24106\" content=\"Primer assaig cl\u00ednic d'un tractament que ataca el c\u00e0ncer de pulm\u00f3 i la met\u00e0stasi al cervell a la vegada\" \/><meta itemprop=\"datePublished\" content=\"2023-08-22\" \/><meta itemprop=\"dateModified\" content=\"2023-08-22\" \/><meta itemprop=\"name\" content=\"IDIBELL\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2023\/03\/cropped-Marca-B.png\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/author\/comunicacio\/\" \/><meta itemprop=\"name\" content=\"comunicacio\" \/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2023\/08\/DSC0853-scaled.jpg\" \/><meta itemprop=\"width\" content=\"2560\" \/><meta itemprop=\"height\" content=\"1704\" \/><meta itemprop=\"interactionType\" content=\"https:\/\/schema.org\/CommentAction\" \/><meta itemprop=\"userInteractionCount\" content=\"0\" \/>\t\n\t\t\t\t<a href=\"https:\/\/idibell.cat\/2023\/08\/primer-assaig-clinic-dun-tractament-que-ataca-el-cancer-de-pulmo-i-la-metastasi-al-cervell-a-la-vegada\/\" title=\"Primer assaig cl\u00ednic d'un tractament que ataca el c\u00e0ncer de pulm\u00f3 i la met\u00e0stasi al cervell a la vegada\"><\/a>\n\t\t\t<a href=\"https:\/\/idibell.cat\/2023\/08\/primer-assaig-clinic-dun-tractament-que-ataca-el-cancer-de-pulmo-i-la-metastasi-al-cervell-a-la-vegada\/\" title=\"Primer assaig cl\u00ednic d'un tractament que ataca el c\u00e0ncer de pulm\u00f3 i la met\u00e0stasi al cervell a la vegada\">Primer assaig cl\u00ednic d&#8217;un tractament que ataca el c\u00e0ncer de pulm\u00f3 i la met\u00e0stasi al cervell a la vegada<\/a>\n\t\t\tBy <a href=\"https:\/\/idibell.cat\/author\/comunicacio\/\">comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t  |  \n\t\t\t\t\t\t\t\t\t22\/08\/2023\t\t\t\t\t\t\t\n\t<meta itemscope itemprop=\"mainEntityOfPage\" itemtype=\"https:\/\/schema.org\/WebPage\" itemid=\"http:\/\/23942\" content=\"Un nou tractament pel c\u00e0ncer de pulm\u00f3 eleva la superviv\u00e8ncia i podria beneficiar a m\u00e9s de 6.000 pacients a l'any\" \/><meta itemprop=\"datePublished\" content=\"2023-06-29\" \/><meta itemprop=\"dateModified\" content=\"2023-06-29\" \/><meta itemprop=\"name\" content=\"IDIBELL\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2023\/03\/cropped-Marca-B.png\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/author\/comunicacio\/\" \/><meta itemprop=\"name\" content=\"comunicacio\" \/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2023\/06\/NP13-E-Nadal_NADIMII-Imatge-noti.jpg\" \/><meta itemprop=\"width\" content=\"1366\" \/><meta itemprop=\"height\" content=\"768\" \/><meta itemprop=\"interactionType\" content=\"https:\/\/schema.org\/CommentAction\" \/><meta itemprop=\"userInteractionCount\" content=\"0\" \/>\t\n\t\t\t\t<a href=\"https:\/\/idibell.cat\/2023\/06\/un-nou-tractament-pel-cancer-de-pulmo-eleva-la-supervivencia-i-podria-beneficiar-a-mes-de-6-000-pacients-a-lany\/\" title=\"Un nou tractament pel c\u00e0ncer de pulm\u00f3 eleva la superviv\u00e8ncia i podria beneficiar a m\u00e9s de 6.000 pacients a l'any\"><\/a>\n\t\t\t<a href=\"https:\/\/idibell.cat\/2023\/06\/un-nou-tractament-pel-cancer-de-pulmo-eleva-la-supervivencia-i-podria-beneficiar-a-mes-de-6-000-pacients-a-lany\/\" title=\"Un nou tractament pel c\u00e0ncer de pulm\u00f3 eleva la superviv\u00e8ncia i podria beneficiar a m\u00e9s de 6.000 pacients a l'any\">Un nou tractament pel c\u00e0ncer de pulm\u00f3 eleva la superviv\u00e8ncia i podria beneficiar a m\u00e9s de 6.000 pacients a l&#8217;any<\/a>\n\t\t\tBy <a href=\"https:\/\/idibell.cat\/author\/comunicacio\/\">comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t  |  \n\t\t\t\t\t\t\t\t\t29\/06\/2023\t\t\t\t\t\t\t\n\t<meta itemscope itemprop=\"mainEntityOfPage\" itemtype=\"https:\/\/schema.org\/WebPage\" itemid=\"http:\/\/22664\" content=\"Un receptor fins ara considerat promotor de mort en c\u00e8l\u00b7lules tumorals podria promoure el creixement del c\u00e0ncer de pulm\u00f3\" \/><meta itemprop=\"datePublished\" content=\"2022-12-28\" \/><meta itemprop=\"dateModified\" content=\"2022-12-28\" \/><meta itemprop=\"name\" content=\"IDIBELL\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2023\/03\/cropped-Marca-B.png\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/author\/comunicacio\/\" \/><meta itemprop=\"name\" content=\"comunicacio\" \/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2022\/12\/NP31-C-Munoz_CDDIS-Imatge-noti.jpg\" \/><meta itemprop=\"width\" content=\"1366\" \/><meta itemprop=\"height\" content=\"768\" \/><meta itemprop=\"interactionType\" content=\"https:\/\/schema.org\/CommentAction\" \/><meta itemprop=\"userInteractionCount\" content=\"0\" \/>\t\n\t\t\t\t<a href=\"https:\/\/idibell.cat\/2022\/12\/un-receptor-fins-ara-considerat-promotor-de-mort-en-cellules-tumorals-podria-promoure-el-creixement-del-cancer-de-pulmo\/\" title=\"Un receptor fins ara considerat promotor de mort en c\u00e8l\u00b7lules tumorals podria promoure el creixement del c\u00e0ncer de pulm\u00f3\"><\/a>\n\t\t\t<a href=\"https:\/\/idibell.cat\/2022\/12\/un-receptor-fins-ara-considerat-promotor-de-mort-en-cellules-tumorals-podria-promoure-el-creixement-del-cancer-de-pulmo\/\" title=\"Un receptor fins ara considerat promotor de mort en c\u00e8l\u00b7lules tumorals podria promoure el creixement del c\u00e0ncer de pulm\u00f3\">Un receptor fins ara considerat promotor de mort en c\u00e8l\u00b7lules tumorals podria promoure el creixement del c\u00e0ncer de pulm\u00f3<\/a>\n\t\t\tBy <a href=\"https:\/\/idibell.cat\/author\/comunicacio\/\">comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t  |  \n\t\t\t\t\t\t\t\t\t28\/12\/2022\t\t\t\t\t\t\t\n\t<meta itemscope itemprop=\"mainEntityOfPage\" itemtype=\"https:\/\/schema.org\/WebPage\" itemid=\"http:\/\/21608\" content=\"Ernest Nadal presenta a ASCO els beneficis de tractar amb quimio-immunoter\u00e0pia als pacients amb c\u00e0ncer de pulm\u00f3 i met\u00e0stasi cerebral\" \/><meta itemprop=\"datePublished\" content=\"2022-06-14\" \/><meta itemprop=\"dateModified\" content=\"2022-06-14\" \/><meta itemprop=\"name\" content=\"IDIBELL\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2023\/03\/cropped-Marca-B.png\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/author\/comunicacio\/\" \/><meta itemprop=\"name\" content=\"comunicacio\" \/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2022\/06\/NO63-E-Nadal_ASCO-Imatge-scaled.jpg\" \/><meta itemprop=\"width\" content=\"2560\" \/><meta itemprop=\"height\" content=\"1441\" \/><meta itemprop=\"interactionType\" content=\"https:\/\/schema.org\/CommentAction\" \/><meta itemprop=\"userInteractionCount\" content=\"0\" \/>\t\n\t\t\t\t<a href=\"https:\/\/idibell.cat\/2022\/06\/ernest-nadal-presenta-a-asco-els-beneficis-de-tractar-amb-quimio-immunoterapia-als-pacients-amb-cancer-de-pulmo-i-metastasi-cerebral\/\" title=\"Ernest Nadal presenta a ASCO els beneficis de tractar amb quimio-immunoter\u00e0pia als pacients amb c\u00e0ncer de pulm\u00f3 i met\u00e0stasi cerebral\"><\/a>\n\t\t\t<a href=\"https:\/\/idibell.cat\/2022\/06\/ernest-nadal-presenta-a-asco-els-beneficis-de-tractar-amb-quimio-immunoterapia-als-pacients-amb-cancer-de-pulmo-i-metastasi-cerebral\/\" title=\"Ernest Nadal presenta a ASCO els beneficis de tractar amb quimio-immunoter\u00e0pia als pacients amb c\u00e0ncer de pulm\u00f3 i met\u00e0stasi cerebral\">Ernest Nadal presenta a ASCO els beneficis de tractar amb quimio-immunoter\u00e0pia als pacients amb c\u00e0ncer de pulm\u00f3 i met\u00e0stasi cerebral<\/a>\n\t\t\tBy <a href=\"https:\/\/idibell.cat\/author\/comunicacio\/\">comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t  |  \n\t\t\t\t\t\t\t\t\t14\/06\/2022\t\t\t\t\t\t\t\n\t<meta itemscope itemprop=\"mainEntityOfPage\" itemtype=\"https:\/\/schema.org\/WebPage\" itemid=\"http:\/\/20509\" content=\"Un model de cuc permet estudiar els efectes adversos de la quimioter\u00e0pia m\u00e9s comuna contra els tumors s\u00f2lids i millorar-ne l&#8217;efectivitat\" \/><meta itemprop=\"datePublished\" content=\"2022-02-16\" \/><meta itemprop=\"dateModified\" content=\"2022-02-16\" \/><meta itemprop=\"name\" content=\"IDIBELL\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2023\/03\/cropped-Marca-B.png\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/author\/comunicacio\/\" \/><meta itemprop=\"name\" content=\"comunicacio\" \/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2022\/02\/NO07-J-Ceron_DMM-Imatge.jpg\" \/><meta itemprop=\"width\" content=\"1366\" \/><meta itemprop=\"height\" content=\"768\" \/><meta itemprop=\"interactionType\" content=\"https:\/\/schema.org\/CommentAction\" \/><meta itemprop=\"userInteractionCount\" content=\"0\" \/>\t\n\t\t\t\t<a href=\"https:\/\/idibell.cat\/2022\/02\/un-model-de-cuc-permet-estudiar-els-efectes-adversos-de-la-quimioterapia-mes-comuna-contra-els-tumors-solids-i-millorar-ne-lefectivitat\/\" title=\"Un model de cuc permet estudiar els efectes adversos de la quimioter\u00e0pia m\u00e9s comuna contra els tumors s\u00f2lids i millorar-ne l&#8217;efectivitat\"><\/a>\n\t\t\t<a href=\"https:\/\/idibell.cat\/2022\/02\/un-model-de-cuc-permet-estudiar-els-efectes-adversos-de-la-quimioterapia-mes-comuna-contra-els-tumors-solids-i-millorar-ne-lefectivitat\/\" title=\"Un model de cuc permet estudiar els efectes adversos de la quimioter\u00e0pia m\u00e9s comuna contra els tumors s\u00f2lids i millorar-ne l&#8217;efectivitat\">Un model de cuc permet estudiar els efectes adversos de la quimioter\u00e0pia m\u00e9s comuna contra els tumors s\u00f2lids i millorar-ne l&#8217;efectivitat<\/a>\n\t\t\tBy <a href=\"https:\/\/idibell.cat\/author\/comunicacio\/\">comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t  |  \n\t\t\t\t\t\t\t\t\t16\/02\/2022\t\t\t\t\t\t\t\n\t<meta itemscope itemprop=\"mainEntityOfPage\" itemtype=\"https:\/\/schema.org\/WebPage\" itemid=\"http:\/\/19910\" content=\"Sara Hijazo, premi a la millor 'comunicaci\u00f3 oral' al XIV\u00e8 Congr\u00e9s de C\u00e0ncer de Pulm\u00f3\" \/><meta itemprop=\"datePublished\" content=\"2021-12-01\" \/><meta itemprop=\"dateModified\" content=\"2021-12-01\" \/><meta itemprop=\"name\" content=\"IDIBELL\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2023\/03\/cropped-Marca-B.png\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/author\/comunicacio\/\" \/><meta itemprop=\"name\" content=\"comunicacio\" \/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2021\/12\/sara-hijazo-2021.jpg_2065046318.jpg\" \/><meta itemprop=\"width\" content=\"450\" \/><meta itemprop=\"height\" content=\"242\" \/><meta itemprop=\"interactionType\" content=\"https:\/\/schema.org\/CommentAction\" \/><meta itemprop=\"userInteractionCount\" content=\"0\" \/>\t\n\t\t\t\t<a href=\"https:\/\/idibell.cat\/2021\/12\/sara-hijazo-premi-a-la-millor-comunicacio-oral-al-xive-congres-de-cancer-de-pulmo\/\" title=\"Sara Hijazo, premi a la millor 'comunicaci\u00f3 oral' al XIV\u00e8 Congr\u00e9s de C\u00e0ncer de Pulm\u00f3\"><\/a>\n\t\t\t<a href=\"https:\/\/idibell.cat\/2021\/12\/sara-hijazo-premi-a-la-millor-comunicacio-oral-al-xive-congres-de-cancer-de-pulmo\/\" title=\"Sara Hijazo, premi a la millor 'comunicaci\u00f3 oral' al XIV\u00e8 Congr\u00e9s de C\u00e0ncer de Pulm\u00f3\">Sara Hijazo, premi a la millor &#8216;comunicaci\u00f3 oral&#8217; al XIV\u00e8 Congr\u00e9s de C\u00e0ncer de Pulm\u00f3<\/a>\n\t\t\tBy <a href=\"https:\/\/idibell.cat\/author\/comunicacio\/\">comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t  |  \n\t\t\t\t\t\t\t\t\t01\/12\/2021\t\t\t\t\t\t\t\n\t<meta itemscope itemprop=\"mainEntityOfPage\" itemtype=\"https:\/\/schema.org\/WebPage\" itemid=\"http:\/\/19283\" content=\"Identifiquen dos f\u00e0rmacs amb activitat antitumoral en models precl\u00ednics de c\u00e0ncer de pleura maligne\" \/><meta itemprop=\"datePublished\" content=\"2021-10-20\" \/><meta itemprop=\"dateModified\" content=\"2021-10-19\" \/><meta itemprop=\"name\" content=\"IDIBELL\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2023\/03\/cropped-Marca-B.png\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/author\/comunicacio\/\" \/><meta itemprop=\"name\" content=\"comunicacio\" \/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2021\/10\/NP38-E-Nadal_BJM-Imatge.jpg\" \/><meta itemprop=\"width\" content=\"1366\" \/><meta itemprop=\"height\" content=\"768\" \/><meta itemprop=\"interactionType\" content=\"https:\/\/schema.org\/CommentAction\" \/><meta itemprop=\"userInteractionCount\" content=\"0\" \/>\t\n\t\t\t\t<a href=\"https:\/\/idibell.cat\/2021\/10\/identifiquen-dos-farmacs-amb-activitat-antitumoral-en-models-preclinics-de-cancer-de-pleura-maligne\/\" title=\"Identifiquen dos f\u00e0rmacs amb activitat antitumoral en models precl\u00ednics de c\u00e0ncer de pleura maligne\"><\/a>\n\t\t\t<a href=\"https:\/\/idibell.cat\/2021\/10\/identifiquen-dos-farmacs-amb-activitat-antitumoral-en-models-preclinics-de-cancer-de-pleura-maligne\/\" title=\"Identifiquen dos f\u00e0rmacs amb activitat antitumoral en models precl\u00ednics de c\u00e0ncer de pleura maligne\">Identifiquen dos f\u00e0rmacs amb activitat antitumoral en models precl\u00ednics de c\u00e0ncer de pleura maligne<\/a>\n\t\t\tBy <a href=\"https:\/\/idibell.cat\/author\/comunicacio\/\">comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t  |  \n\t\t\t\t\t\t\t\t\t20\/10\/2021\t\t\t\t\t\t\t\n\t\t<!-- .pp-content-posts -->\n\n","protected":false},"excerpt":{"rendered":"<p>Recerca precl\u00ednica i experimental dels tumors tor\u00e0cics (PReTT) Resum El grup PReTT es centra en l&#8217;estudi de noves estrat\u00e8gies terap\u00e8utiques en tumors tor\u00e0cics combinant investigaci\u00f3 molecular b\u00e0sica, translacional amb un enfoc orientat al pacient, i bioinform\u00e0tica, aix\u00ed com en el disseny i desenvolupament d&#8217;assajos cl\u00ednics. Pel que fa a la investigaci\u00f3 b\u00e0sica, estudiem els mecanismes [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":448,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"disabled","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"class_list":["post-1732","page","type-page","status-publish","hentry"],"publishpress_future_action":{"enabled":false,"date":"2024-12-29 19:05:18","action":"change-status","newStatus":"draft","terms":[],"taxonomy":""},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/1732","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=1732"}],"version-history":[{"count":8,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/1732\/revisions"}],"predecessor-version":[{"id":26811,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/1732\/revisions\/26811"}],"up":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/448"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=1732"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}